FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2029128580> ?p ?o ?g. }

• W2029128580 endingPage "535" @default.
• W2029128580 startingPage "529" @default.
• W2029128580 abstract "The response of psoriasis to antibodies targeting the interleukin (IL)-23/IL-17A pathway suggests a prominent role of T-helper type-17 (Th17) cells in this disease. We examined the clinical and immunological response patterns of 100 subjects with moderate-to-severe psoriasis receiving 3 different intravenous dosing regimens of the anti-IL-17A antibody secukinumab (1 × 3 mg/kg or 1 × 10 mg/kg on Day 1, or 3 × 10 mg/kg on Days 1, 15 and 29) or placebo in a phase 2 trial. Baseline biopsies revealed typical features of active psoriasis, including epidermal accumulation of neutrophils and formation of microabscesses in >60% of cases. Neutrophils were the numerically largest fraction of infiltrating cells containing IL-17 and may store the cytokine preformed, as IL-17A mRNA was not detectable in neutrophils isolated from active plaques. Significant clinical responses to secukinumab were observed 2 weeks after a single infusion, associated with extensive clearance of cutaneous neutrophils parallel to the normalization of keratinocyte abnormalities and reduction of IL-17-inducible neutrophil chemoattractants (e.g. CXCL1, CXCL8); effects on numbers of T cells and CD11c-positive dendritic cells were more delayed. Histological and immunological improvements were generally dose dependent and not observed in the placebo group. In the lowest-dose group, a recurrence of neutrophils was seen in some subjects at Week 12; these subjects relapsed faster than those without microabscesses. Our findings are indicative of a neutrophil–keratinocyte axis in psoriasis that may involve neutrophil-derived IL-17 and is an early target of IL-17A-directed therapies such as secukinumab." @default.
• W2029128580 created "2016-06-24" @default.
• W2029128580 creator A5000572878 @default.
• W2029128580 creator A5000823009 @default.
• W2029128580 creator A5001708247 @default.
• W2029128580 creator A5004621751 @default.
• W2029128580 creator A5006934805 @default.
• W2029128580 creator A5008079321 @default.
• W2029128580 creator A5008286260 @default.
• W2029128580 creator A5018577996 @default.
• W2029128580 creator A5021178774 @default.
• W2029128580 creator A5024740873 @default.
• W2029128580 creator A5028299043 @default.
• W2029128580 creator A5028439900 @default.
• W2029128580 creator A5029971595 @default.
• W2029128580 creator A5032315045 @default.
• W2029128580 creator A5055020479 @default.
• W2029128580 creator A5059659054 @default.
• W2029128580 creator A5069977428 @default.
• W2029128580 creator A5070278946 @default.
• W2029128580 creator A5070363670 @default.
• W2029128580 creator A5087491297 @default.
• W2029128580 creator A5089460088 @default.
• W2029128580 creator A5089953149 @default.
• W2029128580 creator A5090252753 @default.
• W2029128580 creator A5091166524 @default.
• W2029128580 date "2015-05-08" @default.
• W2029128580 modified "2023-10-17" @default.
• W2029128580 title "Evidence that a neutrophil–keratinocyte crosstalk is an early target of <scp>IL</scp> ‐17A inhibition in psoriasis" @default.
• W2029128580 cites W1499490558 @default.
• W2029128580 cites W1508752722 @default.
• W2029128580 cites W1587526075 @default.
• W2029128580 cites W1968669292 @default.
• W2029128580 cites W1973354423 @default.
• W2029128580 cites W1976291381 @default.
• W2029128580 cites W1979058179 @default.
• W2029128580 cites W1981177225 @default.
• W2029128580 cites W1982598880 @default.
• W2029128580 cites W1987392209 @default.
• W2029128580 cites W1988546322 @default.
• W2029128580 cites W2000851235 @default.
• W2029128580 cites W2022917731 @default.
• W2029128580 cites W2076794463 @default.
• W2029128580 cites W2080705760 @default.
• W2029128580 cites W2083340757 @default.
• W2029128580 cites W2096620879 @default.
• W2029128580 cites W2103018315 @default.
• W2029128580 cites W2104182956 @default.
• W2029128580 cites W2112128505 @default.
• W2029128580 cites W2115528273 @default.
• W2029128580 cites W2116956799 @default.
• W2029128580 cites W2118273159 @default.
• W2029128580 cites W2127834887 @default.
• W2029128580 cites W2129059285 @default.
• W2029128580 cites W2130117150 @default.
• W2029128580 cites W2151209321 @default.
• W2029128580 cites W2152335168 @default.
• W2029128580 cites W2153511580 @default.
• W2029128580 cites W2322390243 @default.
• W2029128580 cites W2561759163 @default.
• W2029128580 cites W4248269869 @default.
• W2029128580 doi "https://doi.org/10.1111/exd.12710" @default.
• W2029128580 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4676308" @default.
• W2029128580 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25828362" @default.
• W2029128580 hasPublicationYear "2015" @default.
• W2029128580 type Work @default.
• W2029128580 sameAs 2029128580 @default.
• W2029128580 citedByCount "141" @default.
• W2029128580 countsByYear W20291285802015 @default.
• W2029128580 countsByYear W20291285802016 @default.
• W2029128580 countsByYear W20291285802017 @default.
• W2029128580 countsByYear W20291285802018 @default.
• W2029128580 countsByYear W20291285802019 @default.
• W2029128580 countsByYear W20291285802020 @default.
• W2029128580 countsByYear W20291285802021 @default.
• W2029128580 countsByYear W20291285802022 @default.
• W2029128580 countsByYear W20291285802023 @default.
• W2029128580 crossrefType "journal-article" @default.
• W2029128580 hasAuthorship W2029128580A5000572878 @default.
• W2029128580 hasAuthorship W2029128580A5000823009 @default.
• W2029128580 hasAuthorship W2029128580A5001708247 @default.
• W2029128580 hasAuthorship W2029128580A5004621751 @default.
• W2029128580 hasAuthorship W2029128580A5006934805 @default.
• W2029128580 hasAuthorship W2029128580A5008079321 @default.
• W2029128580 hasAuthorship W2029128580A5008286260 @default.
• W2029128580 hasAuthorship W2029128580A5018577996 @default.
• W2029128580 hasAuthorship W2029128580A5021178774 @default.
• W2029128580 hasAuthorship W2029128580A5024740873 @default.
• W2029128580 hasAuthorship W2029128580A5028299043 @default.
• W2029128580 hasAuthorship W2029128580A5028439900 @default.
• W2029128580 hasAuthorship W2029128580A5029971595 @default.
• W2029128580 hasAuthorship W2029128580A5032315045 @default.
• W2029128580 hasAuthorship W2029128580A5055020479 @default.
• W2029128580 hasAuthorship W2029128580A5059659054 @default.
• W2029128580 hasAuthorship W2029128580A5069977428 @default.
• W2029128580 hasAuthorship W2029128580A5070278946 @default.
• W2029128580 hasAuthorship W2029128580A5070363670 @default.
• W2029128580 hasAuthorship W2029128580A5087491297 @default.

• next